index: hide

#### Initial Systemic Therapy Options
##### Squamous Cell Carcinoma (PS 0-1)
- No contraindications to the addition of pembrolizumabc
  - Pembrolizumab/carboplatin/paclitaxel {gen.nscl.principles.j.'31},d  (category 1) (preferred)
  - Pembrolizumab/carboplatin/albumin-bound paclitaxel {gen.nscl.principles.j.'31},d  (category 1) (preferred)
  - Pembrolizumab/cisplatin/paclitaxel d
  - Pembrolizumab/cisplatin/albumin-bound paclitaxel d
- Contraindications to the addition of pembrolizumab c
  - Carboplatin/albumin-bound paclitaxel (category 1) {gen.nscl.principles.j.'7}
  - Carboplatin/docetaxel (category 1) {gen.nscl.principles.j.'8}
  - Carboplatin/gemcitabine (category 1) {gen.nscl.principles.j.'11}
  - Carboplatin/paclitaxel (category 1) {gen.nscl.principles.j.'12}
  - Cisplatin/docetaxel (category 1) {gen.nscl.principles.j.'8}
  - Cisplatin/etoposide (category 1) {gen.nscl.principles.j.'14}
  - Cisplatin/gemcitabine (category 1) {gen.nscl.principles.j.'12},{gen.nscl.principles.j.'15}
  - Cisplatin/paclitaxel (category 1) {gen.nscl.principles.j.'16}
  - Gemcitabine/docetaxel (category 1) {gen.nscl.principles.j.'17}
  - Gemcitabine/vinorelbine (category 1) {gen.nscl.principles.j.'18}

##### Squamous Cell Carcinoma (PS 2)
- Albumin-bound paclitaxel {gen.nscl.principles.j.'19}
- Carboplatin/albumin-bound paclitaxel {gen.nscl.principles.j.'20},{gen.nscl.principles.j.'21}
- Carboplatin/docetaxel {gen.nscl.principles.j.'8}
- Carboplatin/etoposide 9,10
- Carboplatin/gemcitabine {gen.nscl.principles.j.'11}
- Carboplatin/paclitaxel {gen.nscl.principles.j.'12}
- Docetaxel {gen.nscl.principles.j.'22},{gen.nscl.principles.j.'23}
- Gemcitabine {gen.nscl.principles.j.'24},{gen.nscl.principles.j.'25},{gen.nscl.principles.j.'26}
- Gemcitabine/docetaxel {gen.nscl.principles.j.'17}
- Gemcitabine/vinorelbine {gen.nscl.principles.j.'18}
- Paclitaxel {gen.nscl.principles.j.'27},{gen.nscl.principles.j.'28},{gen.nscl.principles.j.'29}

 <sup>a</sup>  Albumin-bound paclitaxel may be substituted for either paclitaxel or docetaxel in patients who have experienced hypersensitivity reactions after receiving paclitaxel or docetaxel despite premedication, or for patients where the standard premedications (ie, dexamethasone, H2 blockers, H1 blockers) are contraindicated.

 <sup>b</sup>  Carboplatin-based regimens are often used for patients with comorbidities or those who cannot tolerate cisplatin.

 <sup>c</sup>  Contraindications for treatment with PD-1/PD-L1 inhibitors may include active or previously documented autoimmune disease and/or current use of immunosuppressive d agents or presence of an oncogene, which would predict lack of benefit.

 <sup>d</sup>  If progression on PD-1/PD-L1 inhibitor, switching to another PD-1/PD-L1 inhibitor is not routinely recommended.

 <sup>h</sup>  Cisplatin/gemcitabine/necitumumab in the first-line setting and afatinib in the second-line setting are not used at NCCN Member Institutions for these indications related to the efficacy and safety of these agents compared to the efficacy and safety of other available agents.
